These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 30645635)

  • 1. Competing risks of major bleeding and thrombotic events with prasugrel-based dual antiplatelet therapy after stent implantation - An observational analysis from BASKET-PROVE II.
    Jeger RV; Pfisterer M; Vogt DR; Galatius S; Abildgaard U; Naber C; Alber H; Eberli F; Kurz DJ; Pedrazzini G; Vuilliomenet A; Weilenmann D; Rickli H; Hansen KW; Rickenbacher P; Conen D; Müller C; Osswald S; Gilgen N; Kaiser C
    PLoS One; 2019; 14(1):e0210821. PubMed ID: 30645635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy).
    Stefanescu Schmidt AC; Kereiakes DJ; Cutlip DE; Yeh RW; D'Agostino RB; Massaro JM; Hsieh WH; Mauri L;
    Circulation; 2017 May; 135(18):1720-1732. PubMed ID: 28228427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study.
    Secemsky EA; Yeh RW; Kereiakes DJ; Cutlip DE; Steg PG; Massaro JM; Apruzzese PK; Mauri L;
    JACC Cardiovasc Interv; 2017 May; 10(9):942-954. PubMed ID: 28473118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
    Mauri L; Kereiakes DJ; Yeh RW; Driscoll-Shempp P; Cutlip DE; Steg PG; Normand SL; Braunwald E; Wiviott SD; Cohen DJ; Holmes DR; Krucoff MW; Hermiller J; Dauerman HL; Simon DI; Kandzari DE; Garratt KN; Lee DP; Pow TK; Ver Lee P; Rinaldi MJ; Massaro JM;
    N Engl J Med; 2014 Dec; 371(23):2155-66. PubMed ID: 25399658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    ; Bittl JA; Baber U; Bradley SM; Wijeysundera DN
    Circulation; 2016 Sep; 134(10):e156-78. PubMed ID: 27026019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Aspirin-Free Versus Dual Antiplatelet Strategy for Coronary Stenting: STOPDAPT-3 Randomized Trial.
    Natsuaki M; Watanabe H; Morimoto T; Yamamoto K; Obayashi Y; Nishikawa R; Ando K; Domei T; Suwa S; Ogita M; Isawa T; Takenaka H; Yamamoto T; Ishikawa T; Hisauchi I; Wakabayashi K; Onishi Y; Hibi K; Kawai K; Yoshida R; Suzuki H; Nakazawa G; Kusuyama T; Morishima I; Ono K; Kimura T
    Circulation; 2024 Feb; 149(8):585-600. PubMed ID: 37994553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2-Year Outcomes of High Bleeding Risk Patients After Polymer-Free Drug-Coated Stents.
    Garot P; Morice MC; Tresukosol D; Pocock SJ; Meredith IT; Abizaid A; Carrié D; Naber C; Iñiguez A; Talwar S; Menown IBA; Christiansen EH; Gregson J; Copt S; Hovasse T; Lurz P; Maillard L; Krackhardt F; Ong P; Byrne J; Redwood S; Windhövel U; Greene S; Stoll HP; Urban P;
    J Am Coll Cardiol; 2017 Jan; 69(2):162-171. PubMed ID: 27806919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance of PRECISE-DAPT Score for Predicting Bleeding Complication During Dual Antiplatelet Therapy.
    Choi SY; Kim MH; Cho YR; Sung Park J; Min Lee K; Park TH; Yun SC
    Circ Cardiovasc Interv; 2018 Dec; 11(12):e006837. PubMed ID: 30545256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombotic complications associated with early and late nonadherence to dual antiplatelet therapy.
    Cutlip DE; Kereiakes DJ; Mauri L; Stoler R; Dauerman HL;
    JACC Cardiovasc Interv; 2015 Mar; 8(3):404-410. PubMed ID: 25703885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin: Final Results of the ITALIC Trial (Is There a Life for DES After Discontinuation of Clopidogrel).
    Didier R; Morice MC; Barragan P; Noryani AAL; Noor HA; Majwal T; Hovasse T; Castellant P; Schneeberger M; Maillard L; Bressolette E; Wojcik J; Delarche N; Blanchard D; Jouve B; Ormezzano O; Paganelli F; Levy G; Sainsous J; Carrie D; Furber A; Berlan J; Darremont O; Le Breton H; Lyuycx-Bore A; Gommeaux A; Cassat C; Kermarrec A; Cazaux P; Druelles P; Dauphin R; Armengaud J; Dupouy P; Champagnac D; Ohlmann P; Ben Amer H; Kiss RG; Ungi I; Gilard M
    JACC Cardiovasc Interv; 2017 Jun; 10(12):1202-1210. PubMed ID: 28641840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates.
    Valgimigli M; Patialiakas A; Thury A; McFadden E; Colangelo S; Campo G; Tebaldi M; Ungi I; Tondi S; Roffi M; Menozzi A; de Cesare N; Garbo R; Meliga E; Testa L; Gabriel HM; Airoldi F; Ferlini M; Liistro F; Dellavalle A; Vranckx P; Briguori C;
    J Am Coll Cardiol; 2015 Mar; 65(8):805-815. PubMed ID: 25720624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial.
    Camaro C; Damen SA; Brouwer MA; Kedhi E; Lee SW; Verdoia M; Barbieri L; Rognoni A; van T Hof AW; Ligtenberg E; de Boer MJ; Suryapranata H; De Luca G
    Am Heart J; 2016 Aug; 178():37-44. PubMed ID: 27502850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Bittl JA; Baber U; Bradley SM; Wijeysundera DN
    J Am Coll Cardiol; 2016 Sep; 68(10):1116-39. PubMed ID: 27036919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial.
    Wiviott SD; Braunwald E; McCabe CH; Horvath I; Keltai M; Herrman JP; Van de Werf F; Downey WE; Scirica BM; Murphy SA; Antman EM;
    Lancet; 2008 Apr; 371(9621):1353-63. PubMed ID: 18377975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial.
    Gilard M; Barragan P; Noryani AAL; Noor HA; Majwal T; Hovasse T; Castellant P; Schneeberger M; Maillard L; Bressolette E; Wojcik J; Delarche N; Blanchard D; Jouve B; Ormezzano O; Paganelli F; Levy G; Sainsous J; Carrie D; Furber A; Berland J; Darremont O; Le Breton H; Lyuycx-Bore A; Gommeaux A; Cassat C; Kermarrec A; Cazaux P; Druelles P; Dauphin R; Armengaud J; Dupouy P; Champagnac D; Ohlmann P; Endresen K; Benamer H; Kiss RG; Ungi I; Boschat J; Morice MC
    J Am Coll Cardiol; 2015 Mar; 65(8):777-786. PubMed ID: 25461690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial.
    Watanabe H; Domei T; Morimoto T; Natsuaki M; Shiomi H; Toyota T; Ohya M; Suwa S; Takagi K; Nanasato M; Hata Y; Yagi M; Suematsu N; Yokomatsu T; Takamisawa I; Doi M; Noda T; Okayama H; Seino Y; Tada T; Sakamoto H; Hibi K; Abe M; Kawai K; Nakao K; Ando K; Tanabe K; Ikari Y; Hanaoka KI; Morino Y; Kozuma K; Kadota K; Furukawa Y; Nakagawa Y; Kimura T;
    JAMA; 2019 Jun; 321(24):2414-2427. PubMed ID: 31237644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk.
    Baber U; Leisman DE; Cohen DJ; Gibson CM; Henry TD; Dangas G; Moliterno D; Kini A; Krucoff M; Colombo A; Chieffo A; Sartori S; Witzenbichler B; Steg PG; Pocock SJ; Mehran R
    Circ Cardiovasc Qual Outcomes; 2019 Jan; 12(1):e004945. PubMed ID: 30606052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and predictors of high-on treatment platelet reactivity during prasugrel treatment in patients with acute coronary syndrome undergoing stent implantation.
    Verdoia M; Pergolini P; Nardin M; Rolla R; Barbieri L; Marino P; Carriero A; Suryapranata H; De Luca G;
    J Cardiol; 2019 Mar; 73(3):198-203. PubMed ID: 30522897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation.
    Musumeci G; Rossini R; Lettieri C; Capodanno D; Romano M; Rosiello R; Guagliumi G; Valsecchi O; Gavazzi A; Angiolillo DJ
    Catheter Cardiovasc Interv; 2012 Sep; 80(3):395-405. PubMed ID: 22109961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-Hospital Bleeding and Utility of a Maintenance Dose of Prasugrel 2.5 mg in High Bleeding Risk Patients With Acute Coronary Syndrome.
    Ohya M; Shimada T; Osakada K; Kuwayama A; Miura K; Murai R; Amano H; Kubo S; Otsuru S; Habara S; Tada T; Tanaka H; Fuku Y; Katoh H; Goto T; Kadota K
    Circ J; 2018 Jun; 82(7):1874-1883. PubMed ID: 29695656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.